Scientists make advance in cancer research

January 3, 2014, University of East Anglia

A protein that has been at the centre of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).
The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer.

But research published today in the American Heart Association's journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of tumours. Not least because the drugs targeting it cause minimal side effects compared to other drugs – which can cause bleeding in the gut and .

Tumours must recruit their own supply to grow beyond a very small size. The research team studied the cells that line () in mice, and in particular the role of a widely expressed protein called beta3-integrin.

Dr Stephen Robinson, from UEA's school of Biological Sciences, said: "This protein has been the focus of over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment.

"The most advanced of these drugs, however, has recently failed a phase III clinical trial to treat an aggressive form of . In line with other clinical work, patients respond to treatment for a short while but then their cancers escape the treatment.

"This research helps to explain why these very promising drugs aren't meeting with the success that was anticipated and it suggests a way forward - how to make them work better.

"We have shown how tumours continue to grow despite treatment which should block blood vessel recruitment. They modulate how they are recruiting their blood vessels by using a different pathway from the one that is being targeted. We have identified some molecular changes in endothelial cells that occur with long-term inhibition of beta3-integrin that might help the cells escape the beta3-integrin blockade.

"Our research also shows that timing is critical when targeting the protein beta3-integrin.

"Importantly, these findings have re-established the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be re-focused to either develop new drugs to target beta3-integrin, or figure out how to more effectively use the drugs that already exist."

'Acute Depletion of Endothelial beta3-Integrin Transiently Inhibits Tumour Growth and Angiogenesis in Mice' is published in the journal Circulation Research.

Explore further: Discovery could lead to anti-clotting drugs with less risk of bleeding

Related Stories

Discovery could lead to anti-clotting drugs with less risk of bleeding

October 28, 2013
Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, ...

Targeting protein could prevent metastasis of cancer cells

November 14, 2012
(Medical Xpress)—Researchers at King's College London have uncovered a protein required by cancer cells to spread to other parts of the body, highlighting it as a potential target for future treatments to prevent secondary ...

Partially blocking blood vessels' energy source may stop cancer growth, blindness, other conditions

December 12, 2013
Inhibiting the formation of new blood vessels is a common strategy for treating a range of conditions such as cancer, inflammatory diseases, and age-related macular degeneration. Unfortunately, drug inefficiency, resistance, ...

New target for the fight against cancer as a result of excessive blood vessel formation

August 1, 2013
New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, the success of these treatments ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.